Literature DB >> 1947862

The cost of schizophrenia revisited.

G Andrews1.   

Abstract

This article discusses two approaches to costing disease and summarizes an incidence-based costing of schizophrenia using 1975 data. Because the presentation of schizophrenia may have changed in the last 16 years, the effects of three possible changes--a reduction in incidence, a transfer to treatment in the community, and an improvement in prognosis--are all entered into the 1975 model and the changes in costs are noted. The decrease in costs is greatest presuming a reduction in incidence, moderate given an improvement in prognosis, and relatively minor given the economies in direct treatment costs likely to follow a transfer to community treatment. Nevertheless, because community treatment might also be associated with an improvement in prognosis, the social issues for medicine implicit in the transfer from hospital to community treatment are discussed.

Entities:  

Mesh:

Year:  1991        PMID: 1947862     DOI: 10.1093/schbul/17.3.389

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  3 in total

1.  Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Authors:  A Fitton; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

2.  Cost-effectiveness over 10 years. A study of community-based social psychiatric care in the 1980s.

Authors:  J P Dauwalder; L Ciompi
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1995-07       Impact factor: 4.328

3.  Economic burden of schizophrenia in South Korea.

Authors:  Sung Man Chang; Seong-Jin Cho; Hong Jin Jeon; Bong-Jin Hahm; Hyo Jung Lee; Jong-Ik Park; Maeng Je Cho
Journal:  J Korean Med Sci       Date:  2008-04       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.